Cargando…

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer

PURPOSE: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is standard of care for muscle-invasive bladder cancer (MIBC). However, NAC is used in less than 20% of patients with MIBC. Our goal is to investigate factors that contribute to underutilization NAC to facili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalho, Filipe LF., Zeymo, Alexander, Egan, Jillian, Kelly, Colleen H., Zheng, Chaoyi, Lynch, John H., Hwang, Jonathan, Stamatakis, Lambros, Krasnow, Ross E., Kowalczyk, Keith J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329637/ https://www.ncbi.nlm.nih.gov/pubmed/32665995 http://dx.doi.org/10.4111/icu.2020.61.4.390

Ejemplares similares

Neoadjuvant Chemotherapy in Invasive Bladder Cancer
por: Oliver, R.T.D.
Publicado: (1991)

Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy
por: Carvalho, Filipe L. F., et al.
Publicado: (2019)

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Miyagi, Hiroko, et al.
Publicado: (2022)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
por: Sherif, Amir, et al.
Publicado: (2018)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
por: van Hoogstraten, Lisa M. C., et al.
Publicado: (2023)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer
por: Baird, Bryce, et al.
Publicado: (2023)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
por: Eldefrawy, Ahmed, et al.
Publicado: (2012)

Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Marcq, Gautier, et al.
Publicado: (2019)

Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer
por: Sawasdee, Anupong, et al.
Publicado: (2022)

Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy
por: Sui, Wilson, et al.
Publicado: (2017)

Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer
por: Beije, N., et al.
Publicado: (2022)

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Guancial, Elizabeth A., et al.
Publicado: (2016)

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report
por: Prelaj, Arsela, et al.
Publicado: (2016)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
por: Cowan, N. G., et al.
Publicado: (2014)

Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
por: Xylinas, Evanguelos, et al.
Publicado: (2016)

Excisional biopsy of an extravesicular hemangioma
por: Goldman, Charlotte, et al.
Publicado: (2017)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Pyeloduodenal fistula complicating neoadjuvant chemotherapy in a patient diagnosed with muscle invasive bladder cancer
por: Alanee, Shaheen
Publicado: (2019)

Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Hepburn, Anastasia C., et al.
Publicado: (2021)

The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
por: D'Andrea, David, et al.
Publicado: (2022)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
por: Plambeck, Benjamin D., et al.
Publicado: (2023)

Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial
por: Hinsenveld, F. J., et al.
Publicado: (2021)

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
por: Shi, Hongzhe, et al.
Publicado: (2021)

Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience
por: Agrawal, Chinmayee, et al.
Publicado: (2020)

Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience
por: Yu, Bin, et al.
Publicado: (2015)

Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy
por: Font, Albert, et al.
Publicado: (2020)

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
por: D’Andrea, David, et al.
Publicado: (2020)

Metabolic Profiling of Bladder Cancer Patients’ Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy
por: Zhuang, Juntao, et al.
Publicado: (2022)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
por: Lee, Cheng-Yen, et al.
Publicado: (2014)

Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer
por: Rimar, Kalen J., et al.
Publicado: (2018)

What happens to the patients with muscle-invasive bladder cancer who refuse cystectomy after neoadjuvant chemotherapy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
por: Del Bene, Gabriella, et al.
Publicado: (2018)

Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade
por: Goel, Sunny, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_snmmsuk018c8e37g9130of76ao